Efficacy And Tolerability In An Open-Label Phase I/Ii Study Of Mek Inhibitor Trametinib (T), Braf Inhibitor Dabrafenib (D), And Anti-Egfr Antibody Panitumumab (P) In Combination In Patients (Pts) With Braf V600e Mutated Colorectal Cancer (Crc).